11,000,000 Units Deep Medicine Acquisition Corp. UNDERWRITING AGREEMENTUnderwriting Agreement • November 1st, 2021 • Deep Medicine Acquisition Corp. • Blank checks • New York
The undersigned, Deep Medicine Acquisition Corp., a Delaware corporation (“Company”), hereby confirms its agreement with I-Bankers Securities, Inc. (hereinafter referred to as “you”, “I-Bankers”, or as the “Representative”) and with the other underwriters named on Schedule A hereto for which you are acting as representative (the Representative and the other Underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”), as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 1st, 2021 • Deep Medicine Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 26, 2021, is made and entered into by and among Deep Medicine Acquisition Corp., a Delaware corporation (the “Company”) and Bright Vision Sponsor LLC, a Delaware limited liability company (the “Sponsor”) and the other undersigned parties listed under Holders on the signature page hereto (together with the Sponsor, each a “Holder” and collectively the “Holders”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • November 1st, 2021 • Deep Medicine Acquisition Corp. • Blank checks • New York
This Investment Management Trust Agreement (this “Agreement”) is made effective as of October 26, 2021 by and between Deep Medicine Acquisition Corp., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Trustee”).
I-Bankers Securities, Inc. Keller, TX 76248Deep Medicine Acquisition Corp. • November 1st, 2021 • Blank checks • New York
This is to confirm our agreement whereby Deep Medicine Acquisition Corp., a Delaware corporation (“Company”), has requested I-Bankers Securities, Inc. (the “Advisor”) to serve as the Company’s advisor in connection with the Company effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination (in each case, a “Business Combination”) with one or more businesses (each a “Target”) as described in the Company’s Registration Statements on Form S-1 (File Nos. 333-259500 and 333-260515) filed with the U.S. Securities and Exchange Commission in connection with its initial public offering (“IPO”).
RIGHTS AGREEMENTRights Agreement • November 1st, 2021 • Deep Medicine Acquisition Corp. • Blank checks • New York
This Rights Agreement (this “Agreement”) is made as of October 26, 2021 by and between Deep Medicine Acquisition Corp., a Delaware company with offices at 595 Madison Avenue, 12th Floor, New York, NY 10017 (the “Company”) and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, with offices at 6201 15th Avenue, Brooklyn, NY 11219 (“Rights Agent”).
PRIVATE PLACEMENT UNITS PURCHASE AGREEMENTPrivate Placement Units Purchase Agreement • November 1st, 2021 • Deep Medicine Acquisition Corp. • Blank checks • New York
This Private Placement Units Purchase Agreement (this “Agreement”) is made as of the 26th day of October, 2021, by and among Deep Medicine Acquisition Corp., a Delaware corporation (the “Company”), having its principal place of business at 595 Madison Avenue, 12th Floor, New York, NY 10017, Bright Vision Sponsor LLC, a Delaware limited liability company (the “Sponsor”), having its principal place of business at 595 Madison Avenue, 12th Floor, New York, NY 10017, and I-Bankers Securities, Inc., (“I-Bankers”, together with the Sponsor, “Subscribers”).
October 26, 2021Letter Agreement • November 1st, 2021 • Deep Medicine Acquisition Corp. • Blank checks • New York
This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and among Deep Medicine Acquisition Corp., a Delaware corporation (the “Company”), and I-Bankers Securities, Inc., as representative (the “Representative”) of the several underwriters (each, an “Underwriter” and collectively, the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of 12,650,000 of the Company’s units (including up to 1,650,000 units that may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one share of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), and one right. Each right (a “Right”) entitles the holder thereof to receive one-tenth (1/10) of one share of Common Stock. The Units will be sold in the Public Offering pursuant to a registration statements on Form S-1 (File Nos. 333-259500 and 333-260515) and
